2014 News Releases

Webcast ImageWebcast
NeuroDerm Q4 and Full Year 2016 Financial Results (Live)
03/30/17 at 8:30 a.m. ET

NeuroDerm Q4 and Full Year 2016 Financial Results
Thursday, March 30, 2017 8:30 a.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013 | 2012
DateTitle 
12/30/14NeuroDerm Announces Topline Results of Phase IIa Pharmacokinetic Study of ND0612H and ND0612L, Continuous, Subcutaneously Delivered Levodopa/Carbidopa for the Treatment of Parkinson's Disease
REHOVOT, Israel, Dec. 30, 2014 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical-stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced that continuous, subcutaneous delivery of the company's proprietary liquid levodopa/carbidopa (LD/CD) product candidates, ND0612H and ND0612L, led to clinically-significant plasma levodopa levels. These results suggest that the high dose version, ND0612H, intended for severe Parkinson's disease patient... 
Printer Friendly Version
12/18/14NeuroDerm Announces Third Quarter 2014 Financial Results and Provides a Corporate Update
REHOVOT, Israel, Dec. 18, 2014 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced financial results for the third quarter ended September 30, 2014 and provided a corporate update. Recent Highlights On October 29, 2014, NeuroDerm announced results of a randomized, placebo-controlled, double-blind Phase II clinical study in moderate to severe Parkinson's disease patients. ... 
Printer Friendly Version
12/05/14NeuroDerm CEO to Present at Oppenheimer Healthcare Conference on December 10, 2014
REHOVOT, Israel, Dec. 5, 2014 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced that Oded S. Lieberman, PhD, CEO will present at the Oppenheimer 25th Annual Healthcare Conference on December 10th, 2014 at 8:35am ET in New York. Dr. Lieberman will give a corporate overview and discuss the company's next-generation treatments for central nervous system disorders, including the compan... 
Printer Friendly Version
11/14/14NeuroDerm Announces Pricing of Initial Public Offering
Rehovot, Israel. – November 13, 2014 – NeuroDerm Ltd., a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced the pricing of its initial public offering of 4,500,000 ordinary shares at a price to the public of $10.00 per share. In addition, NeuroDerm has granted the underwriters a 30-day option to purchase up to an additional 675,000 ordinary shares. NeuroDerm shares are expected to begin trading on the Nasdaq Global Market on November... 
Printer Friendly Version
11/03/14NeuroDerm Announces Launch of Initial Public Offering
Rehovot, Israel. – November 3, 2014 – NeuroDerm Ltd., a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced the launch of its initial public offering of 4,500,000 ordinary shares pursuant to a registration statement on Form F-1 filed with the U.S. Securities and Exchange Commission (SEC). NeuroDerm has applied to list its ordinary shares on the Nasdaq Global Market under the ticker symbol “NDRM.” Jefferies LLC and Cowen and Company, ... 
Printer Friendly Version
09/15/14NeuroDerm Ltd. Files Registration Statement for Proposed Initial Public Offering
Rehovot, September 15, 2014 / — NeuroDerm Ltd., a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced that it has filed a registration statement on Form F-1 with the U.S. Securities and Exchange Commission for a proposed initial public offering of its ordinary shares. The number of shares to be offered and the price range for the proposed offering have not yet been determined. NeuroDerm has applied to list its ordinary shares on the N... 
Printer Friendly Version
09/03/14NeuroDerm Announces Start of Phase 2a Study of Continuous Subcutaneous Liquid Levodopa/Carbidopa Administration for Patients with Severe Parkinson’s Disease
Continuous levodopa therapy with ND0612H has the potential to prevent or delay the need for surgical intervention in patients with severe stage Parkinson’s diseaseREHOVOT, September 03, 2014 / — NeuroDerm Ltd., a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced that the first patients with severe Parkinson’s disease have been enrolled and dosed in a Phase IIa trial of ND0612H. ND0612H is a high-dose form of NeuroDerm’s proprietary ... 
Printer Friendly Version
08/21/14NeuroDerm Secures $16 Million Financing Round
REHOVOT, Israel (August 21, 2014) — NeuroDerm Ltd., a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced that it has signed definitive investment agreements for a $16 million financing round led by certain of its existing investors with the participation of new investors, including The Elias Group. The company plans to use the funding to further the clinical and regulatory development of its product pipeline, primarily its continuous... 
Printer Friendly Version
08/04/14NeuroDerm Announces Eligibility for European Union Centralized Procedure for ND0612H, a Novel Treatment for Advanced Parkinson’s Disease
REHOVOT, Israel (August 4, 2014) — NeuroDerm Ltd. today announced that the European Medicines Agency (EMA) has deemed ND0612H, its product candidate offering continuous delivery of levodopa/carbidopa (LD/CD) treatment for advanced Parkinson’s disease, eligible for a European Union marketing authorization application procedure (“centralized procedure”). According to EMA guidelines, the EMA can allow products for which the centralized procedure is not mandatory to use that procedure, if the EMA co... 
Printer Friendly Version
03/11/14NeuroDerm Announces Enrollment in a Second Phase 2 Study of ND0612L, a Continuous Levodopa/Carbidopa Drug for the Treatment of Parkinson’s Disease
REHOVOT, Israel, March 11, 2014 /– NeuroDerm, Ltd. announced today that enrollment of patients is ongoing in its second Phase II clinical trial of ND0612L, a novel drug formulation for the treatment of Parkinson’s disease. ND0612L is a proprietary levodopa/carbidopa liquid formulation under development for continuous subcutaneous administration through a patch pump. It is designed to provide steady levodopa blood levels for the treatment of Parkinson’s disease. In previous phase I and phase II... 
Printer Friendly Version